Gain of function mutation of the α7 nicotinic receptor: Distinct pharmacology of the human α7V274T variant

Clark A. Briggs, David G. McKenna, Lisa M Monteggia, Edward Touma, Jean Marc Roch, Stephen P. Arneric, Murali Gopalakrishnan, James P. Sullivan

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

In the human α7 nicotinic receptor, valine-274 in the pore-lining transmembrane-2 region was mutated to threonine to produce the variant human α7V274T, which was evaluated electrophysiologically following expression in Xenopus laevis oocytes. Inward current rectification was strong in human α7V274T as in the human α7 wild type nicotinic receptor. However, human α7V274T was 100-fold more sensitive to the nicotinic receptor agonists acetylcholine, (-)-nicotine and 1,1-dimethyl-4-phenylpiperazinium. Choline also activated human α7V274T (EC50=12 μM) and was 82-fold more potent than at human α7 wild type nicotinic receptor. (-)-Cotinine, (2,4)-dimethoxybenzylidene anabaseine (GTS-21) and 2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine (ABT-089), weak partial agonists at human α7 wild type, were much stronger agonists at human α7V274T with EC50 values of 70 μM, 4 μM and 28 μM and fractional activation values of 93%, 96% and 40%, respectively. However, (-)-lobeline, a human α7 wild type nicotinic receptor antagonist, and dihydro-β-erythroidine, which activates chick mutagenized α7 nicotinic receptors, had only weak agonist-like activity at human α7V274T (≤4% of the maximal acetylcholine response). Methyllycaconitine, mecamylamine, d-tubocurarine and dihydro-β-erythroidine retained antagonist activity and, indeed, appeared to be at least as potent at human α7V274T as at human α7 wild type. These results support and extend the concept that human nicotinic receptor pharmacology can be profoundly altered by single amino acid changes in the pore-lining segment. Copyright (C) 1999 Elsevier Science B.V.

Original languageEnglish (US)
Pages (from-to)301-308
Number of pages8
JournalEuropean Journal of Pharmacology
Volume366
Issue number2-3
DOIs
StatePublished - Feb 5 1999

Fingerprint

Nicotinic Receptors
Pharmacology
Mutation
Acetylcholine
Lobeline
Nicotinic Agonists
Nicotinic Antagonists
Mecamylamine
Cotinine
Tubocurarine
Xenopus laevis
Valine
Threonine
Choline
Nicotine
Human Activities
Oocytes

Keywords

  • Dihydro-β-erythroidine
  • Human
  • Mecamylamine
  • Methyllycaconitine
  • Nicotinic receptor
  • Oocyte, Xenopus laevis

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Briggs, C. A., McKenna, D. G., Monteggia, L. M., Touma, E., Roch, J. M., Arneric, S. P., ... Sullivan, J. P. (1999). Gain of function mutation of the α7 nicotinic receptor: Distinct pharmacology of the human α7V274T variant. European Journal of Pharmacology, 366(2-3), 301-308. https://doi.org/10.1016/S0014-2999(98)00909-1

Gain of function mutation of the α7 nicotinic receptor : Distinct pharmacology of the human α7V274T variant. / Briggs, Clark A.; McKenna, David G.; Monteggia, Lisa M; Touma, Edward; Roch, Jean Marc; Arneric, Stephen P.; Gopalakrishnan, Murali; Sullivan, James P.

In: European Journal of Pharmacology, Vol. 366, No. 2-3, 05.02.1999, p. 301-308.

Research output: Contribution to journalArticle

Briggs, CA, McKenna, DG, Monteggia, LM, Touma, E, Roch, JM, Arneric, SP, Gopalakrishnan, M & Sullivan, JP 1999, 'Gain of function mutation of the α7 nicotinic receptor: Distinct pharmacology of the human α7V274T variant', European Journal of Pharmacology, vol. 366, no. 2-3, pp. 301-308. https://doi.org/10.1016/S0014-2999(98)00909-1
Briggs, Clark A. ; McKenna, David G. ; Monteggia, Lisa M ; Touma, Edward ; Roch, Jean Marc ; Arneric, Stephen P. ; Gopalakrishnan, Murali ; Sullivan, James P. / Gain of function mutation of the α7 nicotinic receptor : Distinct pharmacology of the human α7V274T variant. In: European Journal of Pharmacology. 1999 ; Vol. 366, No. 2-3. pp. 301-308.
@article{49784ac43b2d4bbca043b3a6f6a86b4b,
title = "Gain of function mutation of the α7 nicotinic receptor: Distinct pharmacology of the human α7V274T variant",
abstract = "In the human α7 nicotinic receptor, valine-274 in the pore-lining transmembrane-2 region was mutated to threonine to produce the variant human α7V274T, which was evaluated electrophysiologically following expression in Xenopus laevis oocytes. Inward current rectification was strong in human α7V274T as in the human α7 wild type nicotinic receptor. However, human α7V274T was 100-fold more sensitive to the nicotinic receptor agonists acetylcholine, (-)-nicotine and 1,1-dimethyl-4-phenylpiperazinium. Choline also activated human α7V274T (EC50=12 μM) and was 82-fold more potent than at human α7 wild type nicotinic receptor. (-)-Cotinine, (2,4)-dimethoxybenzylidene anabaseine (GTS-21) and 2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine (ABT-089), weak partial agonists at human α7 wild type, were much stronger agonists at human α7V274T with EC50 values of 70 μM, 4 μM and 28 μM and fractional activation values of 93{\%}, 96{\%} and 40{\%}, respectively. However, (-)-lobeline, a human α7 wild type nicotinic receptor antagonist, and dihydro-β-erythroidine, which activates chick mutagenized α7 nicotinic receptors, had only weak agonist-like activity at human α7V274T (≤4{\%} of the maximal acetylcholine response). Methyllycaconitine, mecamylamine, d-tubocurarine and dihydro-β-erythroidine retained antagonist activity and, indeed, appeared to be at least as potent at human α7V274T as at human α7 wild type. These results support and extend the concept that human nicotinic receptor pharmacology can be profoundly altered by single amino acid changes in the pore-lining segment. Copyright (C) 1999 Elsevier Science B.V.",
keywords = "Dihydro-β-erythroidine, Human, Mecamylamine, Methyllycaconitine, Nicotinic receptor, Oocyte, Xenopus laevis",
author = "Briggs, {Clark A.} and McKenna, {David G.} and Monteggia, {Lisa M} and Edward Touma and Roch, {Jean Marc} and Arneric, {Stephen P.} and Murali Gopalakrishnan and Sullivan, {James P.}",
year = "1999",
month = "2",
day = "5",
doi = "10.1016/S0014-2999(98)00909-1",
language = "English (US)",
volume = "366",
pages = "301--308",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Gain of function mutation of the α7 nicotinic receptor

T2 - Distinct pharmacology of the human α7V274T variant

AU - Briggs, Clark A.

AU - McKenna, David G.

AU - Monteggia, Lisa M

AU - Touma, Edward

AU - Roch, Jean Marc

AU - Arneric, Stephen P.

AU - Gopalakrishnan, Murali

AU - Sullivan, James P.

PY - 1999/2/5

Y1 - 1999/2/5

N2 - In the human α7 nicotinic receptor, valine-274 in the pore-lining transmembrane-2 region was mutated to threonine to produce the variant human α7V274T, which was evaluated electrophysiologically following expression in Xenopus laevis oocytes. Inward current rectification was strong in human α7V274T as in the human α7 wild type nicotinic receptor. However, human α7V274T was 100-fold more sensitive to the nicotinic receptor agonists acetylcholine, (-)-nicotine and 1,1-dimethyl-4-phenylpiperazinium. Choline also activated human α7V274T (EC50=12 μM) and was 82-fold more potent than at human α7 wild type nicotinic receptor. (-)-Cotinine, (2,4)-dimethoxybenzylidene anabaseine (GTS-21) and 2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine (ABT-089), weak partial agonists at human α7 wild type, were much stronger agonists at human α7V274T with EC50 values of 70 μM, 4 μM and 28 μM and fractional activation values of 93%, 96% and 40%, respectively. However, (-)-lobeline, a human α7 wild type nicotinic receptor antagonist, and dihydro-β-erythroidine, which activates chick mutagenized α7 nicotinic receptors, had only weak agonist-like activity at human α7V274T (≤4% of the maximal acetylcholine response). Methyllycaconitine, mecamylamine, d-tubocurarine and dihydro-β-erythroidine retained antagonist activity and, indeed, appeared to be at least as potent at human α7V274T as at human α7 wild type. These results support and extend the concept that human nicotinic receptor pharmacology can be profoundly altered by single amino acid changes in the pore-lining segment. Copyright (C) 1999 Elsevier Science B.V.

AB - In the human α7 nicotinic receptor, valine-274 in the pore-lining transmembrane-2 region was mutated to threonine to produce the variant human α7V274T, which was evaluated electrophysiologically following expression in Xenopus laevis oocytes. Inward current rectification was strong in human α7V274T as in the human α7 wild type nicotinic receptor. However, human α7V274T was 100-fold more sensitive to the nicotinic receptor agonists acetylcholine, (-)-nicotine and 1,1-dimethyl-4-phenylpiperazinium. Choline also activated human α7V274T (EC50=12 μM) and was 82-fold more potent than at human α7 wild type nicotinic receptor. (-)-Cotinine, (2,4)-dimethoxybenzylidene anabaseine (GTS-21) and 2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine (ABT-089), weak partial agonists at human α7 wild type, were much stronger agonists at human α7V274T with EC50 values of 70 μM, 4 μM and 28 μM and fractional activation values of 93%, 96% and 40%, respectively. However, (-)-lobeline, a human α7 wild type nicotinic receptor antagonist, and dihydro-β-erythroidine, which activates chick mutagenized α7 nicotinic receptors, had only weak agonist-like activity at human α7V274T (≤4% of the maximal acetylcholine response). Methyllycaconitine, mecamylamine, d-tubocurarine and dihydro-β-erythroidine retained antagonist activity and, indeed, appeared to be at least as potent at human α7V274T as at human α7 wild type. These results support and extend the concept that human nicotinic receptor pharmacology can be profoundly altered by single amino acid changes in the pore-lining segment. Copyright (C) 1999 Elsevier Science B.V.

KW - Dihydro-β-erythroidine

KW - Human

KW - Mecamylamine

KW - Methyllycaconitine

KW - Nicotinic receptor

KW - Oocyte, Xenopus laevis

UR - http://www.scopus.com/inward/record.url?scp=0033030490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033030490&partnerID=8YFLogxK

U2 - 10.1016/S0014-2999(98)00909-1

DO - 10.1016/S0014-2999(98)00909-1

M3 - Article

C2 - 10082212

AN - SCOPUS:0033030490

VL - 366

SP - 301

EP - 308

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 2-3

ER -